LY01015

Phase 3Small molecule

SShandong Boan Biotechnology Co., Ltd

LY01015 is one of 48 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaActive, not recruiting

Esophageal Squamous Cell CarcinomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

241 competitors in Esophageal Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

30 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

31 3

Camptosar

Pfizer

Phase 3

11 4

Keytruda

Merck & Co.

Phase 3

8 5

Imfinzi

AstraZeneca

Phase 3

4 6

Eloxatin

Teva

Phase 3

4 7

Tecentriq

Roche

Phase 3

2 8

Opdivo

Bristol-Myers Squibb

Phase 3

2 9

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

9 10

Bayer Aspirin

Bayer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Esophageal Squamous Cell Carcinoma

NCT06022861

Clinical

Trials by Indication[1]

Esophageal Squamous Cell Carcinoma1 trial

A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Recruiting·SShandong Boan Biotechnology Co., Ltd·Phase 3·NCT06022861·510 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LY01015. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LY01015 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LY01015. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shandong Boan Biotechnology Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SShandong Boan Biotechnology Co., Ltd

LY01015

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Esophageal Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News